ArticleInternational journal of biological sciences2026
Comprehensive Metabolomic Profiling of Skin Lesions from Psoriasis Patients Reveals Disease Signatures.
Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic skin disease caused by dysregulated immune system. Although inflammation plays a vital role, the precise chemical changes within the skin remain unclear and metabolomic profiling of skin lesions has been limited by small sample sizes and narrow metabolite coverage. In this study, we performed wide-targeted metabolomics of skin samples from 30 psoriasis patients and 30 healthy controls to identify differential metabolites that may drive the disease. We identified 707 differential metabolites across 21 classes, including amino acids, fatty acids, organic acids, nucleotides, and others. Among them, two metabolites, UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine and ethylparaben, were strongly linked to psoriasis. Further analysis revealed that these changes were driven by specific differentiated keratinocytes and involved metabolomic enzyme-encoding genes related to nucleotide and pyrimidine metabolism pathways. To identify metabolites associated with disease severity, we grouped patients by PASI and BSA scores and identified 27 metabolites that increased as the disease worsened via Mfuzz clustering analysis. Among them, citrate and L-tyrosine significantly exacerbated disease by increasing skin thickness and inflammation after validation in vivo. Our findings provide a comprehensive map of metabolic changes in psoriatic skin and highlight citrate and L-tyrosine as potential indicators for disease severity and promising targets for future treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.